semaglutide cardiovascular outcomes news 2025 october of and tirzepatide for patients with type 2 diabetes in clinical practice Semaglutide and Cardiovascular Outcomes in

Exclusion criteria for participation included contraindications to MRI, inability to read or understand English, concussion within the past three months, neurological, psychiatric, or systemic disorders (e.g., attention deficit hyperactivity disorder (ADHD), autism, developmental delay, intellectual disability psychosis, schizophrenia) or major comorbidities such as epilepsy or arthritis

Yes, as with other incretin-based therapies, nausea, diarrhea, and reduced appetite are among the most commonly reported side effects, especially during dose escalation

Quantification of whole-body and segmental skeletal muscle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices

1) Patient Selection & Baseline Workup Type 2 Diabetes: Candidates with suboptimal A1C despite lifestyle +/- oral agents

Recomendada en aquellas personas que hagan ejercicio de forma regular y para deportistas que quieran bajar de peso